JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Qualitative Study of Black-White Sleep Disparities

  NCT03389828

  Condition:   Sleep Health
  Intervention:  
  Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
  Recruiting
• SelectSecure 3830 Lead Imaging

  NCT03941275

  Condition:   Heart Diseases
  Intervention:   Diagnostic Test: Bi-plane fluoroscopy
  Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

  NCT03521154

  Condition:   Non Small Cell Lung Cancer (Stage III)
  Interventions:   Drug: Osimertinib 80mg/40mg;   Drug: Placebo Osimertinib 80mg/40mg
  Sponsor:   AstraZeneca
  Recruiting
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123

  Condition:   Triple Negative Breast Neoplasms
  Interventions:   Drug: Capivasertib;   Drug: Paclitaxel;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

  NCT03833154

  Condition:   Carcinoma, Non-Small-Cell Lung
  Interventions:   Drug: Durvalumab;   Other: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Durvalumab;   Other: Placebo;   Drug: Carboplatin/Paclitaxel;   Drug: Cisplatin/Gemcitabine;   Drug: Pemetrexed/Cisplatin;   Drug: Pemetrexed/Carboplatin
  Sponsor:   AstraZeneca
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

  NCT03692403

  Condition:   Endometriosis-related Pain
  Interventions:   Drug: Quinagolide 360 µg;   Drug: Quinagolide 720 µg;   Drug: Quinagolide 1080 µg;   Drug: Placebo
  Sponsor:   Ferring Pharmaceuticals
  Recruiting
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

  NCT03447769

  Condition:   Non-Small Cell Lung Cancer
  Interventions:   Drug: Canakinumab;   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

  NCT03398655

  Condition:   Recurrent Platinum Resistant Ovarian Cancer
  Interventions:   Drug: VB-111 + Paclitaxel;   Drug: Placebo + Paclitaxel
  Sponsors:   Vascular Biogenics Ltd. operating as VBL Therapeutics;   GOG Foundation, Inc.
  Recruiting
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

  NCT03219333

  Conditions:   Carcinoma, Transitional Cell;   Urinary Bladder Neoplasms;   Urologic Neoplasms;   Renal Pelvis Neoplasms;   Urothelial Cancer;   Ureteral Neoplasms;   Urethral Neoplasms
  Intervention:   Drug: Enfortumab vedotin
  Sponsors:   Astellas Pharma Global Development, Inc.;   Seattle Genetics, Inc.
  Recruiting
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755

  Condition:   Breast Cancer
  Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

  NCT03053193

  Condition:   Breast Cancer
  Intervention:   Diagnostic Test: MammaPrint, BluePrint, and Full-Genome Testing
  Sponsor:   Agendia
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• 3T MRI CIED Post-Approval Study

  NCT02969395

  Condition:   Cardiac Rhythm Disorder
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting